共 50 条
- [1] Biomarkers and surrogate end points in clinical trials of tuberculosis treatment - Reply to Davies et al.JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (04): : 649 - 650Walzl, GerhardMistry, RohitDockrell, Hazel M.van Helden, Paul D.Cliff, Jacqueline M.
- [2] Biomarkers as Surrogate End Points in Heart Failure TrialsHEART FAILURE CLINICS, 2011, 7 (04) : 501 - +Felker, G. Michael
- [3] A regulatory agency's perspective on the application of biomarkers and surrogate end points in clinical trialsBIOMARKERS AND SURROGATE ENDPOINTS: CLINICAL RESEARCH AND APPLICATIONS, 2000, 1205 : XIV - XVIIIHenney, J
- [4] Surrogate End Points and Their Validation in Oncology Clinical TrialsJOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (13) : 1436 - +Zhao, Fengmin
- [5] Biomarkers and Surrogate End points in Multiple Sclerosis Trials: Regulatory IssuesJOURNAL OF CLINICAL NEUROPHYSIOLOGY, 2021, 38 (03) : 181 - 185Skeen, Mark B.Pani, Luca
- [6] The Use of Modified Surrogate End Points in Cancer Clinical TrialsCANCER INVESTIGATION, 2022, 40 (01) : 14 - 16Al Hadidi, Samer
- [7] Surrogate end points for clinical trials of kidney disease progressionCLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (04): : 874 - 884Stevens, Lesley A.Greene, TomLevey, Andrew S.
- [8] Surrogate end points in clinical trials: Are we being misled?ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) : 605 - 613Fleming, TRDeMets, DL
- [9] Outcomes and costs of Surrogate End-points (SES) and biomarkers in phase I oncology clinical trialsVALUE IN HEALTH, 2004, 7 (03) : 248 - 248Goulart, BHLRoberts, TGLiu, YClark, JW
- [10] Validation of surrogate end points in multiple randomized clinical trials with failure time end pointsJOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2001, 50 : 405 - 422Burzykowski, TMolenberghs, G